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HIV-1 Gag amino acid substitutions associated with protease inhibitor (PI) treatment have mainly been reported
in subtype B, while information on other subtypes is scarce. Using sequences from 11613 patients infected with
different HIV-1 subtypes, we evaluated the prevalence of 93 Gag amino acid substitutions and their association with
genotypic PI resistance. A significant association was found for 13 Gag substitutions, including A431V in both subtype B
and CRF01_AE. K415R in subtype C and S451G in subtype B were newly identified. Most PI-associated Gag substitutions
are located in the flexible C-terminal domain, revealing the key role this region plays in PI resistance.
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An amino acid substitution is commonly defined as an
amino acid change between two consecutive sequences
based on longitudinal data [1,2]. Amino acid substitutions
in HIV-1 protease, commonly called resistance mutations
if they confer HIV-1 drug resistance, are known to emerge
under selective pressure of protease inhibitors (PIs) [3]. As
an alternative mechanism, HIV-1 can escape PI selective
pressure by the selection of substitutions in the protease
substrate Gag [1,4-7]. Such Gag substitutions arising
during PI-based treatment have mostly been characterized
in HIV-1 subtype B (Additional file 1: Table S1), while
only a few studies have focused on non-B subtypes
using small cohorts of patients (Table 1). Gag variability
has been shown to impact PI susceptibility in a subtype-
dependent manner [4,6], warranting a comprehensive
analysis of PI-associated Gag substitutions across different* Correspondence: annemie.vandamme@uzleuven.be
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unless otherwise stated.subtypes. Here, we identified novel Gag substitutions
in HIV-1 non-B subtypes using longitudinal data from
patients failing PI-based therapy. Moreover, we evaluated
the prevalence of the newly identified and the previously
reported Gag substitutions in different HIV-1 subtypes
and investigated their association with genotypic PI
resistance using a large sequence dataset.
We first investigated the emergence of non-B Gag sub-
stitutions during PI-based treatment in a cohort of 1068
patients followed at the University Hospital of Leuven, for
which virological outcome and treatment information
were available [12]. Our protocol and quality control of
viral sequencing and viral load tests have been described
previously [13,14]. For 69 patients infected with HIV-1
non-B subtypes and receiving PI-based treatment for at
least three months, sequence information for Gag, prote-
ase and reverse transcriptase (RT) was available at baseline
and at treatment failure, which was defined according to
the guidelines of the European AIDS Clinical Society
(EACS) (http://www.eacsociety.org/). Under drug selective
pressure, 21 different substitutions at 18 Gag positions
were identified among 12 patients, of whom 11 harbored
Gag substitutions in the presence of (pre-existing or
simultaneously acquired) drug resistance mutations inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of Gag amino acid substitutions in HIV-1 non-B subtypes observed during PI-based treatment
Gag amino acid substitutions in non-B subtypes* Number of patients infected
by non-B subtypes
Reference
A431V A or F# (n = 4) [8]
K436R, N451S C (n = 1) [8]
L363F, A364G, A374T, I376V, M378V, R380K, K436E, G443R G (n = 2), 01_AE (n = 1), 02_AG (n = 4) [9]
V128A/T/I, Q130R, Y132F, V135M, V362I, A373T, A374T, A375T, I376A/V/M, K380R,
S381G, N382K, E428D/Q, Q430R/G/V/I, A431V, K436R, L449I, N451S, R452K, P453I
G (n = 21) [10]
N375S, G381R A1 (n = 2) [2]
G381S, G446E 02_AG (n = 1) [2]
V135I, I376V, L486F 01_AE (n = 1) [2]
P453L/T/I F# (n = 61) [11]
M138L, F363L, L363W, A374T, V374A, R387K, N389T, K411Q, K415R, G420A,
P422Q, T427P, P445L, S451G, R452G, P453L, P453Ins, I469T, P472S, P474L, E477Q
A1 (n = 1), C (n = 6), D (n = 1), F1 (n = 1),
J (n = 1), 01_AE (n = 1), 02_AG (n = 1)
Our study
*Non-B Gag substitutions reported during PI-based treatment. The substitutions are summarized based on the original publications, and for the substitutions in
our study, it is given relative to the baseline sequences sampled from individual patients (see Figure 1). The substitutions also identified in subtype B are indicated
in bold. Additional file 1: Table S1 summarizes the information of Gag substitutions in HIV-1 subtype B.
#Information of HIV-1 subtype or sub-subtype was ambiguous or not available.
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Gag substitution P453Ins (insertion: EPTAPP) emerged
in patient 343 in the absence of PI and RTI resistance
mutations. Some substitutions were from a less to a
more common amino acid such as M138L. Specifically,
patients failing LPV/r-based regimens developed one of
the following Gag substitution patterns: L363W+E477Q,
F363L +N389T + P422Q+ P455L, K411Q, P472S + P474L,
K415R + I469T, M138L, A374T or G420A. Patients failing
DRV/r-based regimens developed Gag substitution patterns
P453Ins or T427P + R452G. Patients failing an ATV/r-
based regimen developed Gag substitution patterns: P453L
or V374A+R387K + S451G+ P453Ins. A patient failing a
regimen containing FPV/r and SQV/r developed L363W.
Longitudinal data from 34 PI-naïve patients infected with
non-B subtypes revealed the emergence of one Gag substi-
tution (V370A) in a single patient. Overall, when analyzing
all subtypes, the proportion of PI-treated patients with
Gag substitutions was much higher than that of PI-naïve
patients (17.4% (12/69) vs 2.9% (1/34), p-value = 0.037).
For our second analysis, we compiled a comprehensive
list of 93 Gag substitutions at 55 positions in B and
non-B subtypes observed in PI-treated patients, based
on literature results or our first analysis as described
above (Table 1, Additional file 1: Table S1). Next, we
systematically evaluated the prevalence of these variants
in major HIV-1 subtypes using 10865 full-length Gag
sequences retrieved from the HIV Los Alamos database
(one sequence per patient) (Table 2). Sequence alignment
and quality control have been described previously [15].
We found that the prevalence of 62 (66.7%) Gag variants
at 39 positions was above 1% in at least one subtype or
CRF (A1, B, C, D, F1, G, CRF01_AE, CRF02_AG).
Among the 55 Gag positions, only 363 and 455 were highly
conserved with less than 1% overall amino acid variation inevery subtype and CRF in our dataset (Figure 2A). Moreover,
77 of these 93 variants (82.8%) were found at 42 positions
located in the Gag C-terminal domain (positions: 362-500).
As treatment information of the 10865 full-length gag
nucleotide sequences was largely lacking, our third
analysis aimed to evaluate whether these 93 Gag variants
were significantly associated with genotypic PI resistance.
Among the 11613 sequences pooled from the Leuven and
the Los Alamos datasets (Table 2), 6645 spanned both
the gag and the full-length protease regions, and were
translated into amino acid sequences for our analysis.
Using the drug resistance interpretation algorithms
HIVdb V7.0 [16] and Rega V9.1 [17], 660 sequences were
concordantly estimated to be partially or fully resistant to
at least one PI, and 5657 sequences were concordantly
estimated to be fully susceptible to all PIs (Additional
file 1: Table S3). Sequences with discordant estimates of
PI susceptibility were excluded from our analysis. Fisher’s
exact tests were then used to compare the amino acid
prevalence between these PI-susceptible and PI-resistant
datasets. Of the 93 Gag variants, 16 at 13 amino acid
positions were associated with (partial or full) PI resistance
in at least one HIV-1 subtype (p-value < 0.05, Additional
file 1: Table S4). After multiple testing correction using
the false discovery rate approach described in [18], 13 Gag
variants at 10 positions remained significantly PI-associated
within individual subtypes (adjusted p-value < 0.05), includ-
ing 11 variants located in the Gag C-terminal domain
(Figure 2B, Table 3). Our analysis successfully identified the
known PI-associated Gag substitution A431V, strengthen-
ing the validity of our approach. As the only PI-associated
Gag substitution found in more than one subtype, A431V
had a high prevalence in the PI-resistant strains of subtype
B (13.5%) and CRF01_AE (18.2%) (Table 3). Interestingly,
of the 21 Gag substitutions observed in our first analysis,
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  RT: 103N+108I+179L+189I+215Y+238T
AZT+3TC+EFV
ATV/r, D4T+DDI
Gag: 427T+452R
  PR: 74S
  RT: 67[N,D]+184[I,M]
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Gag: 363W+477Q
  PR: 10V+20T
  RT: 103N+108I+
         179L+189I
         +215Y+238T
AZT+3TC+EFV
DRV/r, AZT+3TC+TDF
FTC+TDF+EFV
3TC+ABC+AZT
Gag: 363L+389T+422Q+445L
  PR: 74S
Gag: 427P+452G
  PR: 62[I,V]+74S
  RT: 184V
Gag: 374A+387K+451G+453Ins
  RT: 184[I,M]
Gag: 415K+469T
  PR: 62[I,L]Gag: 415K+469T
Gag: 415K+469T
Gag: 415R+469T
  PR: 62[I,V]
Gag: 
415K+469I
Gag: 374T
  PR: 10I+20R+54V+ 62V+82A
  RT: 67N+70R+101E
Gag: 411K
  RT: 75[I,V]+103N+215[T,I]
ABC+3TC+TDF
ATV/r, FTC+TDF
Gag: 453P
 PR: 10V+62V
LPV/r, 
3TC+TDF
FPV/r, 3TC+ABC+TDF
Mut 1: 10I+33F+43T+48V+54V
            +62V+74S+82A+89I
Gag: 363L
  PR: Mut 1
  RT: Mut 4
Gag: 411Q
  RT: 67N+70R+101[K,E]+
         184V+190A+219[K,E]
Gag: 427T+452R
  PR: 62[I,V]+74S
  RT: 67[N,D]+184V
Gag: 427T+452R
  PR: 62[I,V]+74S
Mut 2: 41L+44D+67N+106M+118I+184V
            +190A+210W+215Y+219N+227L
Mut 3: 41L+44D+67N+101[K,E]+106[I,M,V]+118I
           +184[M,V]+190A+210W+215Y+219N+227L
Mut 4: 41L+44D+67N+101[K,E]+118I+184[M,V]
           +190A+210W+215Y+219N+227L
Gag: 363L
  PR: Mut 1
  RT: Mut 2
Figure 1 Gag substitutions and PI or RTI resistance mutations in 12 patients from the Leuven cohort. Each subplot shows the data of one
patient regarding the viral load, the treatment period and the emerging Gag substitutions and the PI/RTI resistance mutations. X- and Y-axes indicate
the time (weeks) and the level of plasma HIV RNA (log10 copies/mL), respectively. For each subplot, red dots indicate the level of viral load and the
dash line indicates the viral load cutoff at 50 copies per mL. Beneath the viral load plot, each treatment period is annotated by a colored bar with
vertical black lines indicating the sequence sampling time. The blue, pink, green and yellow bars show PI-based treatments containing LPV/r,
FPV/r, ATV/r and DRV/r, respectively. The grey bar indicates treatments lacking PIs. Multiple substitutions or mutations are shown using the
plus symbol “+”. Amino acids translated from ambiguous nucleotide letters are indicated by brackets. For patient 343, the insertion EPTAPP at
position P453 is annotated as P453Ins. For patient 1075, the sets of PI or RTI resistance mutation are abbreviated (Mut 1-4) and listed in the
subplot. Additional file 1: Table S2 provides the full list of Gag, protease and RT substitutions in these 12 patients.
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Table 2 Summary of Leuven and Los Alamos sequence datasets
Subtype Los Alamos dataset Leuven dataset Total number
of patientNumber of Gag sequence* Number of Gag sequence Number of PI-naïve patient Number of PI-treated patient
A1 1648 167 72 19 1739
B 4131 639 313 57 4501
C 2780 198 58 24 2862
D 443 42 20 9 472
F1 35 38 25 4 64
G 49 1 1 0 50
J 3 8 1 2 6
01_AE 1714 72 45 5 1764
02_AG 62 139 71 22 155
Total 10865 1304 606 142 11613
*Number of Gag sequences in different HIV-1 subtypes (one sequence per patient) [15].
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Figure 2 Prevalence of Gag amino acid variants reported in patients failing PI-based therapies and their mapping to HIV-1 protein
structures. (A) Prevalence of amino acid variations at 55 Gag positions in 8 HIV-1 subtypes (A1, B, C, D, F1, G, 01_AE and 02_AG) given the Los
Alamos full-length Gag sequence dataset (Table 2). Only Gag positions where amino acid substitutions have been observed during PI-based treatment
are shown. For each position, the HXB2 index is shown at the top, followed by the most prevalent amino acids (bold) and amino acid variations in our
sequence datasets. Amino acids with blue superscripts have prevalence above 10% and other amino acids have orange superscripts. (B) Structural
representation of Gag polyprotein and mapping of the 13 PI-associated Gag substitutions identified in Table 3. The annotation of Gag polyproteins is
shown at the top. Individual Gag protein structures are shown at the bottom. Gag substitutions are annotated and colored accordingly. Red surfaces
indicate PI-associated Gag substitutions at the Gag C-terminal domain; other substitutions are shown in green. PDB data of Gag protein structures:
matrix, 1HIW; capsid, 3NTE; p2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. Visualization software: PyMOL V1.5 (http://www.pymol.org/).
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Table 3 Prevalence of PI-associated Gag substitutions in individual HIV-1 subtypes
Gag
substitutions*
Subtype Prevalence# P-value Adjusted
p-valuePI-resistant dataset PI-susceptible dataset
V128I B 5.8% (7/121&) 0.9% (6/638) 0.002 0.024
Y132F B 10.7% (13/122) 3.4% (22/639) 0.004 0.035
K415R C 2.5% (3/119) 0.0% (0/1727) <0.0001 0.012
Q430R C 2.5% (3/119) 0.1% (1/1727) 0.003 0.046
A431V B 13.5% (23/170) 0.1% (1/787) <0.0001 <0.0001
01_AE 18.2% (4/22) 0.7% (8/1111) <0.0001 0.007
I437V B 8.9% (15/168) 1.7% (13/784) <0.0001 <0.0001
L449F B 5.6% (21/377) 0.5% (7/1352) <0.0001 <0.0001
L449V B 4.8% (18/377) 0.9% (12/1352) <0.0001 <0.0001
S451G B 3.4% (13/378) 1.3% (17/1348) 0.008 0.041
S451T B 2.1% (8/378) 0.0% (0/1348) <0.0001 <0.0001
R452S B 3.4% (13/384) 0.3% (4/1374) <0.0001 <0.0001
P453T C 21.8% (26/119) 3.1% (53/1722) <0.0001 <0.0001
P453L B 18.5% (71/384) 7.1% (99/1399) <0.0001 <0.0001
*A list of Gag substitutions whose prevalence differs significantly between sequences estimated to be (fully or partially) PI-resistant and sequences estimated to
be PI-susceptible (see full reports in Additional file 1: Table S4). The substitutions are indicated relative to the consensus amino acids from individual subtypes
[15]. One-tailed Fisher’s exact tests were performed, and p-values were adjusted using multiple testing correction via the false discovery rate (FDR) approach [18].
#Statistical analyses were only performed on individual subtype (B, C, G, 01_AE) datasets, which contained more than 10 (partially or fully) PI-resistant sequences.
Additional file 1: Table S3 summarizes the subtype distribution of PI-resistant and PI-susceptible sequence datasets.
&: The numerator indicates the number of sequences for which the corresponding Gag position is covered; the denominator indicates the number of sequences
displaying the respective amino acid substitutions.
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associated with genotypic PI resistance in subtypes C
and B respectively, suggesting a possible involvement in
PI-resistance.
To our knowledge, this study presents the first large-
scale sequence analysis to establish statistical significance
of PI-associated Gag substitutions in HIV-1 non-B sub-
types. Our longitudinal analysis of a clinical cohort of
patients failing PI-based therapy confirmed that PI-
treated patients developed more Gag substitutions than
PI-naïve patients. The majority of these Gag substitutions
emerged in the context of pre-existing or simultaneously
acquired PI or RTI resistance mutations, confirming the
important role of the known resistance mutations, while
in some patients Gag substitutions emerged in the
absence of resistance mutations (Figure 1, Additional
file 1: Table S2). Such Gag substitutions may therefore
contribute to the virological failure of PI-based treatments.
Based on two widely used genotypic interpretation algo-
rithms, our comparative analysis found that only 13
(13.8%) of the 93 Gag substitutions emerging under PI
selective pressure were significantly associated with
genotypic PI resistance (Table 3). Particularly, the novel
Gag substitutions K415R and S451G were identified in
both our longitudinal and cross-sectional sequence
analyses. This suggests that they may play a role in viral
escape from PI selective pressure, partially contributing to
the observed virological failure. Since virological outcomeand treatment information is lacking for most sequences
extracted from the HIV Los Alamos database, this limits
our analysis to address the clinical impact of the newly
identified substitutions with large-scale data. Using small
cohorts, previous studies suggested that different subtypes
may develop different Gag substitutions [6,19,20]. We
confirmed this hypothesis since only 9 of the 58 Gag
substitutions reported in non-B subtypes (Table 1) were
also observed in subtype B (Additional file 1: Table S1).
Among non-B Gag substitutions, 4 were significantly
associated with genotypic PI resistance, of which only
A431V was PI-associated in subtype B as well (Table 3).
However, further evaluations on subtypes A2, D, F2, J,
K and other CRFs are still needed due to the restriction
of our study to particular subtypes. Interestingly, a pre-
dominant presence of PI-associated Gag substitutions
at the flexible C-terminal domain of Gag (Figure 2B) leads
us to suggest the hypothesis that PI-associated Gag
substitutions tend to emerge in the structural flexible
regions. These Gag substitutions can emerge along
with protease drug resistance mutations as shown in
our longitudinal sequence analysis (Figure 1, Additional
file 1: Table S2) and previous studies [21,22]. Future stud-
ies are still needed to investigate the significance of coevo-
lution between Gag substitutions and protease resistance
mutations.
Overall, our findings showed different PI-associated
substitutions in the Gag C-terminal domain across
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http://www.retrovirology.com/content/11/1/79different subtypes, providing a roadmap to elucidate the
role of Gag amino acid substitutions in the development
of PI resistance.
Our Leuven sequences with associated information are
available through Euresist (http://www.euresist.org). The
protocol and this consent procedure have been approved
by the Ethical Committee UZ Leuven (reference ML-8627,
approval B322201316521 S52637). Our toolbox designed
for visualizing the longitudinal data in Figure 1 is freely
available in Additional file 2: Toolbox S1.
Additional files
Additional file 1: Table S1. Summary of HIV-1 subtype B Gag amino
acid substitutions observed during PI-based treatment. Table S2.
Summary of Gag, protease and RT amino acid substitutions in the Leuven
cohort. Table S3. Summary of PI-resistant and PI-susceptible sequence
datasets. Table S4. Prevalence of Gag amino acid variants in individual
HIV-1 subtypes.
Additional file 2: Software. Toolbox S1: Our Matlab toolbox designed
for visualizing longitudinal data of viral load, treatment period and
sampling time.
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